-- Shanghai Henlius Biotech (HKG:2696) secured an implied approval for the phase 2/3 clinical trial of HLX43 for injection in Japan by the country's Pharmaceuticals and Medical Devices Agency, according to a Monday Hong Kong bourse filing.
The drug is being tested as monotherapy or in combination with pimurutamab HLX07 versus Docetaxel for advanced squamous non-small cell lung cancer.
The firm will begin the trial once the relevant conditions are fulfilled, the filing said.